Healthcare Industry News: Hodgkin lymphoma
News Release - June 17, 2011
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating OfficerBOTHELL, Wash.--(Healthcare Sales & Marketing Network)-- Seattle Genetics, Inc. (Nasdaq:SGEN ) announced today that Eric L. Dobmeier has been promoted to the newly created position of Chief Operating Officer (COO). Mr. Dobmeier has been with Seattle Genetics for more than nine years, serving most recently as Chief Business Officer.
“Eric is an invaluable member of the leadership team at Seattle Genetics, and this promotion reflects his significant strategic and operational impact,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “I am excited to work with Eric in this broader role as COO as we prepare for the planned launch of ADCETRIS and transition to a commercial organization later this year, advance our earlier-stage product pipeline and evaluate strategic collaborations that support Seattle Genetics’ vision of improving the lives of people with cancer.”
Mr. Dobmeier joined Seattle Genetics in March 2002. In addition to his continued leadership of the business development, legal, communications and project management functions within Seattle Genetics, as COO he will also have responsibility for technical operations and process sciences. During his tenure at Seattle Genetics, Mr. Dobmeier has led negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization agreement with Millennium: The Takeda Oncology Company for brentuximab vedotin (ADCETRIS™) and antibody-drug conjugate (ADC) collaborations with leading biotechnology and pharmaceutical companies. He has also participated in raising more than $600 million in equity financing for Seattle Genetics. Mr. Dobmeier received a law degree from University of California, Berkeley and an undergraduate degree from Princeton University.
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The U.S. Food and Drug Administration has granted priority review to Biologics License Applications for its lead product candidate, brentuximab vedotin (ADCETRIS™), for the treatment of relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma, with a PDUFA date of August 30, 2011. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has five other clinical-stage programs: SGN-75, ASG-5ME, ASG-22ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company’s expectations for regulatory approval and commercial launch of brentuximab vedotin. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that data from our pivotal Hodgkin lymphoma trial and phase II systemic ALCL trial of brentuximab vedotin will not support marketing approval for the submitted indications. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company’s 10-Q for the quarter ended March 31, 2011 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Seattle Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.